Currently, the indications for CD19-CAR-T cells are expanding, serving not only as a crucial bridge for B-ALL patients undergoing allogeneic hematopoietic stem cell transplantation but also for providing long-term remission for patients with multiple myeloma. Here, CD19 is linked to plasma cell myeloma.